Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

References for PMC Articles for PubMed (Select 22248663)

1.

Defining emerging roles for NF-κB in antivirus responses: revisiting the interferon-β enhanceosome paradigm.

Balachandran S, Beg AA.

PLoS Pathog. 2011 Oct;7(10):e1002165. doi: 10.1371/journal.ppat.1002165. Epub 2011 Oct 13. No abstract available.

2.

Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.

Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ.

Hepatology. 2011 Oct;54(4):1135-48. doi: 10.1002/hep.24489. Epub 2011 Aug 11.

3.

Type I interferon production induced by RIG-I-like receptors.

Onomoto K, Onoguchi K, Takahasi K, Fujita T.

J Interferon Cytokine Res. 2010 Dec;30(12):875-81. doi: 10.1089/jir.2010.0117. Review.

PMID:
21121861
4.

Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes.

Podevin P, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet JF, Scatton O, Dreux M, Cosset FL, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y.

Gastroenterology. 2010 Oct;139(4):1355-64. doi: 10.1053/j.gastro.2010.06.058. Epub 2010 Jul 1.

PMID:
20600021
5.

Regulation of adaptive immunity by the innate immune system.

Iwasaki A, Medzhitov R.

Science. 2010 Jan 15;327(5963):291-5. doi: 10.1126/science.1183021. Review.

6.

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M.

Nat Genet. 2009 Oct;41(10):1105-9. doi: 10.1038/ng.449. Epub 2009 Sep 13.

PMID:
19749757
7.

The roles of TLRs, RLRs and NLRs in pathogen recognition.

Kawai T, Akira S.

Int Immunol. 2009 Apr;21(4):317-37. doi: 10.1093/intimm/dxp017. Epub 2009 Feb 26. Review.

8.

Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes.

Walters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, Rice CM, Katze MG.

PLoS Pathog. 2009 Jan;5(1):e1000269. doi: 10.1371/journal.ppat.1000269. Epub 2009 Jan 16.

9.

Innate immunity to virus infection.

Takeuchi O, Akira S.

Immunol Rev. 2009 Jan;227(1):75-86. doi: 10.1111/j.1600-065X.2008.00737.x. Review.

PMID:
19120477
10.

microRNA-122 stimulates translation of hepatitis C virus RNA.

Henke JI, Goergen D, Zheng J, Song Y, Schüttler CG, Fehr C, Jünemann C, Niepmann M.

EMBO J. 2008 Dec 17;27(24):3300-10. doi: 10.1038/emboj.2008.244. Epub 2008 Nov 20.

11.

TLRs and innate immunity.

Beutler BA.

Blood. 2009 Feb 12;113(7):1399-407. doi: 10.1182/blood-2008-07-019307. Epub 2008 Aug 29. Review.

12.

Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation.

Kato T, Choi Y, Elmowalid G, Sapp RK, Barth H, Furusaka A, Mishiro S, Wakita T, Krawczynski K, Liang TJ.

Hepatology. 2008 Sep;48(3):732-40. doi: 10.1002/hep.22422.

13.

Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA.

Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr.

Nature. 2008 Jul 24;454(7203):523-7. doi: 10.1038/nature07106. Epub 2008 Jun 11.

14.

Interferon signaling and treatment outcome in chronic hepatitis C.

Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):7034-9. doi: 10.1073/pnas.0707882105. Epub 2008 May 8.

15.

Viral infections activate types I and III interferon genes through a common mechanism.

Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T.

J Biol Chem. 2007 Mar 9;282(10):7576-81. Epub 2007 Jan 4.

16.

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.

Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group.

Hepatology. 2006 Dec;44(6):1617-25.

PMID:
17133471
17.

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.

Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM.

Gastroenterology. 2006 Dec;131(6):1887-98. Epub 2006 Oct 1.

PMID:
17087946
18.

Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH.

J Virol. 2005 Sep;79(17):11095-104.

19.

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ.

Nat Med. 2005 Jul;11(7):791-6. Epub 2005 Jun 12. Erratum in: Nat Med. 2005 Aug;11(8):905.

20.

Complete replication of hepatitis C virus in cell culture.

Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM.

Science. 2005 Jul 22;309(5734):623-6. Epub 2005 Jun 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk